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Abstract: The ruthenium-based complex [Ru(η6-p-phenylethacrynate)Cl2(pta)]  
(pta = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane), termed ethaRAPTA, is an 
interesting antitumor compound. The elucidation of the molecular mechanism of drug 
activity is central to the drug development program. To this end, we have characterized the 
ethaRAPTA interaction with DNA, including probing the sequence specific modified DNA 
structural stability and DNA amplification using the breast cancer suppressor gene 1 
(BRCA1) of human breast and colon adenocarcinoma cell lines as models. The preference 
of ethaRAPTA base binding is in the order A > G > T > C. Once modified, the 
ethaRAPTA-induced BRCA1 structure has higher thermal stability than the modified 
equivalents of its related compound, RAPTA-C. EthaRAPTA exhibits a higher efficiency 
than RAPTA-C in inhibiting BRCA1 amplification. With respect to both compounds, the 
inhibition of BRCA1 amplification is more effective in an isolated system than in cell lines. 
These data provide evidence that will help to understand the process of elucidating the 
pathways involved in the response induced by ethaRAPTA. 
Keywords: BRCA1; DNA adducts; DNA amplification; ethaRAPTA; tumor  
suppressor gene 
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1. Introduction 
Since the introduction of cisplatin [cis-dichlorodiammineplatinum(II)], and its analog carboplatin 
[cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II)] into clinical practice [1–4] there has been 
much interest in the development of anticancer drugs. Both platinum complexes have a similar 
spectrum of antitumor activity against human testicular, ovarian, urinary bladder and head and neck 
cancers [3] and the mechanism of cytotoxicity is mediated via covalent DNA binding between a 
platinum atom and the N-7 atom of guanine and guanine or adenine. The majority of platinum-DNA 
adducts are intrastrand crosslinks in the order Pt-GG (65%), Pt-AG (25%) to Pt-GNG (6%) [5,6]. 
Minor adducts include interstrand crosslink and the monofunctional adducts. All adducts interfere with 
DNA replication, transcription and translation, and finally leads to the apoptosis pathway and cancer 
cell death. 
Unfortunately, the platinum-based anticancer complexes have some side effects such as 
nephrotoxicity, myelotoxicity, ototoxicity, peripheral neuropathy, nausea and vomiting, 
myelosuppression and thrombocytopenia [3,7]. Furthermore, their clinical utility is limited, and many 
tumor cells are resistant to platinum drugs [8,9]. Where platinum drugs are ineffective, the mortality 
from cancer is significantly higher than when they are effective. For these reasons, new transition 
metal-based compounds are being designed that overcome the platinum complex limitations. 
Ruthenium complexes have properties particularly well suited for medicinal applications [10], 
including relevant ligand exchange kinetics, redox potentials and the ability to mimic iron in binding to 
certain biological molecules [11]. Currently, several generations of ruthenium complexes have been 
synthesized and investigated for their anticancer properties [12]. These ruthenium complexes have a 
different mode of action than the platinum-based drugs and could therefore widen the range of cancers 
that can be treated. 
The ruthenium complexes imidazolium trans-[tetrachlorido(1H-imidazole)(S-dimethyl sulfoxide) 
ruthenate(III)] (NAMI-A) and indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] 
(KP1019) are among the most promising anticancer candidates [12]. Both NAMI-A and KP1019 have 
successfully completed phase 1 clinical trials and NAMI-A entered phase 2 clinical trials in 2008 (in 
combination with a cytotoxic drug), and KP1019 is also undergoing further clinical trials [13]. The 
RAPTA compounds contain a ruthenium(II)-arene unit with a PTA ligand [14]. These complexes have 
been shown to interact with DNA in a pH-dependent manner [15,16] and offer cancer cell specific 
targeting. In the case of the cytotoxicity of the RAPTA complexes on TS/A mouse adenocarcinoma 
cells and on HBL-100 cells (normal human breast epithelial cells), the RAPTA complexes are selective 
towards the TS/A cells whereas cytotoxicity on the HBL-100 cells was not observed [10]. The 
selective cytotoxicity of these RAPTA complexes toward the cancer cells could potentially lead to a 
drug with lower side effects compared to other metal-based anticancer drugs [10]. Although the rate of 
reaction with DNA is significantly lower than that of cisplatin, several RAPTA complexes display 
excellent in vivo activity [10,17]. The prototype compound, [Ru(6-p-cymene)Cl2(PTA)], termed 
RAPTA-C (Figure 1), remains the best characterized complex in the series and the molecular 
mechanism has been shown to involve mitochondrial-induced apoptosis [18]. However, the rate of 
reaction of RAPTA-C with DNA is significantly lower than those of cisplatin or carboplatin. Recently, 
organometallic ruthenium complexes containing ethacrynic acid (EA) ligands have been  
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rationally developed as drugs which selectively bind to glutathione S-transferase (GST) and inhibit  
GST activity [19]. With the validation of ethacraplatin to overcome glutathione S-transferase  
(GST)-mediated drug resistance, a new RAPTA complex with EA tethered to the arene ring 
[(ethacrynic-6-benzylamide)RuCl2(pta) or ethaRAPTA] (Figure 1), was therefore developed, and 
investigated for GST-inhibitory activity and its effect on the proliferation of cancer cells. EthaRAPTA 
was found to inhibit cancer cell growth (A549, HT29, MCF-7, A2780, and A2780cisR cell lines) [19]. 
However, the molecular mechanisms underlying the ethaRAPTA-induced response remain to  
be elucidated. 
Figure 1. Structures of the RAPTA complexes. 
 
BRCA1 is an important tumor suppressor gene in humans. Its translated product, the 220 kDa 
BRCA1 protein, has been shown to play an important role in genomic integrity maintenance  
such as DNA repair, cell-cycle checkpoint control, transcriptional regulation and protein  
ubiquitination [20–22]. Therefore, approaching such a gene as a potentially molecular target for the 
antitumor ruthenium(II)-arene (RAPTA) compounds might be of interest in cancer therapy. Recently, 
the interaction of two RAPTA compounds, RAPTA-C and carboRAPTA-C, with the specified DNA 
sequence of the human breast cancer suppressor gene BRCA1 has been studied [23]. The ruthenation of 
DNA by RAPTA-C was also very similar to the platination value observed for carboplatin. Both 
RAPTA-C and carboRAPTA-C formed different ruthenium-DNA adducts with predominantly 
monofunctional adducts at A and C and, to a lesser extent, at G, which contrasts with the behavior of 
cisplatin [24]. For ethaRAPTA, the Ru-modified BRCA1 may lose its functions in cancerous cells  
that ultimately result in cancer cell death. In the present study, we investigate the interactions  
of ethaRAPTA with the specified DNA sequence of the human BRCA1 gene in cells and a  
cell-free system. 
2. Results and Discussion 
2.1. EthaRAPTA-Mediated Conformational Changes of the Cell-Free BRCA1 Fragment 
The 3'-terminal region of the human BRCA1 gene covering exon 16–24 (nucleotide 4897–5592) 
was used as a model for the ethaRAPTA-mediated retardation of DNA. The electrophoretic mobility of 
ethaRAPTA-treated BRCA1 fragment was reduced as the concentration of ethaRAPTA increased 
(Figure 2). Ruthenation caused a progressive increase in the frequency of DNA lesions. It is interesting 
to note that at a ruthenium concentration of 200 μM, the band disappeared due to aggregation of the 
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ethaRAPTA-BRCA1 adducts and thus inhibited the intercalation of ethidium bromide into the DNA 
molecules at higher levels of ruthenation. 
Figure 2. Electrophoretic mobility of ethaRAPTA-treated BRCA1 fragment. The 696 bp 
BRCA1 fragment (3 μg) was incubated with various concentrations of ethaRAPTA  
(100–1000 μM) at 37 C for 24 h in the dark. Ruthenated DNA was electrophoresed on 1% 
agarose gel. The gel was stained with ethidium bromide and visualized under UV light.  
M = 100 bp DNA ladder, C-1 = untreated DNA (DNA solution in sterile double distilled 
water), C-2 = untreated DNA (DNA solution in DMSO). 
 
Gel electrophoresis was used to study the effect of ethaRAPTA on DNA interstrand crosslinks. 
Under alkaline denaturation, double-stranded DNA is disrupted to a single strand. Both strands migrate 
similarly as the rate is dependent on the size and not the sequence of DNA. The mobility of the DNA 
strands began to change at the ruthenium(II) complex concentration of 50 μM and this change was 
complete at the concentration of 80 μM (Figure 3). At ethaRAPTA concentration of 50 μM, initiation 
of interstrand crosslinks was formed. The intensity of interstrand crosslinks increased as ethaRAPTA 
concentration increased. The complete interstrand crosslinks were formed at ethaRAPTA 
concentration of 80 μM. At a ruthenium concentration of 70 μM or above, the band intensity was 
reduced due to aggregation of the ethaRAPTA-BRCA1 adducts and thus inhibited the intercalation of 
ethidium bromide into the DNA molecules at higher levels of ruthenation. 
Figure 3. Interstrand crosslinks between ethaRAPTA and the BRCA1 fragment. The  
696-bp BRCA1 fragment (3 μg) was incubated with various concentrations of ethaRAPTA 
(20–100 μM) at 37 C for 24 h in the dark. Ruthenated DNA was electrophoresed on 1% 
alkaline agarose gel. The gel was neutralized by neutralizing solution, stained with 
ethidium bromide and visualized under UV light. 
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2.2. The Preference of ethaRAPTA Base Binding is in the Order A > G > T > C 
Preferential sites for ruthenation on the 696-bp fragment of the 3'-terminal region of BRCA1 may be 
deduced from restriction analysis using specific enzymes (EcoO109I and PvuII) that recognize specific 
sequences on the tested gene. The EcoO109I cleaved the gene fragment into two fragments of 283-bp 
and 413-bp and the digestion of PvuII produced two digested fragments of 237-bp and 459-bp which 
can be detected by electrophoresis on an agarose gel. Production of the digested fragments from 
ethaRAPTA-treated DNA in the presence of both EcoO109I (dGpG) and PvuII (dGpC) was inhibited 
at similar concentrations, in a dose-response behavior (Figure 4). At 800 μM or above, the 
ethaRAPTA-treated BRCA1 fragment became resistant to both restriction enzymes. Both enzymes 
showed a similar level of inhibition and with no specificity between the two restriction sites. However, 
these two enzymes were about twice less effective in restriction cleavage when compared with its 
prototype RAPTA-C-treated BRCA1 fragment [23], indicating that the large bulky group of the 
ruthenium center may hinder accessibility by the enzymes to their restriction sites on the DNA 
molecules. In addition, the band intensity was reduced due to aggregation of the ethaRAPTA-BRCA1 
adducts and thus inhibited the intercalation of ethidium bromide into the DNA molecules at higher 
levels of ruthenation. 
Figure 4. Restriction analysis for ruthenation site of the 696-bp BRCA1 fragment. The  
696-bp BRCA1 fragment (3 μg) was incubated with various concentrations of RAPTA-EA1 
(200–1600 μM) at 37 C for 24 h in the dark. The ethaRAPTA-treated DNA was 
precipitated, redissolved in steriled double distilled water and further incubated with  
either EcoO109I or PvuII at 37 C for 5 and 6 h, respectively. Restriction products were 
electrophoresed on 1% agarose gel. The gel was stained with ethidium bromide and 
visualized under UV light. M = 100 bp DNA ladder, C = untreated and uncut DNA. 
 
The sequence specificity of ethaRAPTA-BRCA1 adducts was determined. Sequence analysis 
showed that ethaRAPTA was preferentially attacked by the BRCA1 gene in the order A > G > T > C. 
A possible interstrand crosslinking between the ruthenium atom and the base/sequence of the BRCA1 
fragment is shown in Figure 5. However, no ethaRAPTA-BRCA1 adducts were observed at the 
EcoO109I or PvuII cleavage sites suggesting that the ruthenation with the accessibility or function of 
these endonucleases. The observed ruthenation sites in this study agree very well with NMR, MS and 
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gel electrophoresis studies, suggesting that RAPTA, NAMI-A and KP1019 exhibit similar reactivity 
towards adenine and guanine [13,14]. In addition, it was found that adduct formation of the BRCA1 
fragment induced by RAPTA-C or carboRAPTA-C occurred most frequently at A, C, and G, in that 
order [23]. These crosslinks can be expected based on their different properties of the ruthenium 
complexes [25]. 
Figure 5. Schematic diagram showing base/sequence of the BRCA1 fragment used to 
monitor the inhibition of DNA synthesis on the template modified by ethaRAPTA. The 
arrow indicates the start site and the direction of DNA synthesis. The bars represent 
possible monofunctional crosslinks. TGGGCCC is a recognition sequence of EcoO109I 
and CAGCTG is a recognition sequence of PvuII. Numbers represent the nucleotide 
sequence of cDNA of BRCA1 gene (exon 16–24). 
 
2.3. EthaRAPTA can also Bind to the BRCA1 Fragment through Intercalation 
The absorption spectra of ethaRAPTA, in the absence and the presence of the BRCA1 fragment (at a 
constant concentration of complexes; 1000 μM), is shown in Figure 6. The absorption intensities of 
ethaRAPTA were shown to successively increase and exhibited hyperchromism. This result is similar 
to that reported for the interaction of other types of ruthenium(II) complexes [26–29]. The intrinsic 
binding constant (Kb) of the complex with the BRCA1 fragment was determined as 2.34 × 106 M−1 
from the changes in absorbance at 340 nm using the Equation 1 (see Experimental Section). As a 
result, ethaRAPTA can also bind to the BRCA1 fragment through intercalation [30]. 
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Figure 6. Absorption spectra of ethaRAPTA complex ([Ru] = 1 mM) in the presence  
of increasing concentrations of the 696-bp BRCA1 fragment. The arrow indicated  
the changes in absorbance upon increasing the DNA concentration. Inset: plot of  
[DNA]/(εa − εf) vs. [DNA]. 
 
2.4. Altered Thermal Stability of EthaRAPTA Adducts 
The DNA melting technique is indeed a very popular, sensitive and easy tool to detect even slight 
DNA conformational changes induced by metal complexes and other ligands [31]. As temperature is 
increased, the double-stranded DNA gradually dissociates to a single strand, and generates a 
hypochromic effect on the absorption spectra of DNA bases (λmax = 260 nm). The melting temperature 
(Tm), which is defined as the temperature where half of the total base pairs are dissociated, is 
determined from the thermal denaturation curves of DNA. Difference in melting temperature of DNA 
treated and non-treated by metal complexes can give an insight into the nature of the interaction of the 
metal complexes with DNA. The ΔTm values are small and positive for covalent adducts of monoaqua 
complexes and are large and positive for adducts of diaqua complexes [32]. The positive values of ΔTm 
imply that the covalent adduct is more difficult to melt than the unbound DNA. The DNA melting 
curves for the BRCA1 fragment in the absence or in the presence of the ruthenium(II) complexes  
were shown in Figure 7. When compared with the untreated DNA, the melting temperature increased 
upon treatment with either RAPTA-C or ethaRAPTA, respectively. An increase in DNA melting 
temperature may reflect an increased stability of the helical DNA structure after binding to these 
RAPTA complexes. 
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Figure 7. Thermal denaturation of the 696-bp BRCA1 fragment in the absence (♦) or in the 
presence of RAPTA-C (▲) and ethaRAPTA (■). The 696-bp BRCA1 fragment (3 μg) was 
incubated with either ethaRAPTA or RAPTA-C at 37 C for 24 h in the dark. Thermal 
denaturation was obtained by measuring the absorbance at the wavelength of 260 nm with 
the temperature scanning. The melting temperature (Tm) was taken as a mid-point of the  
melting curves. 
 
2.5. EthaRAPTA Exhibited a Higher Efficiency than RAPTA-C in Inhibiting BRCA1 Amplification  
In order to detect the degree of DNA damage, the quantitative PCR (QPCR) method was used to 
monitor the progress of the Taq DNA polymerase in a PCR that utilized the DNA adducts as templates. 
Previous reports have shown that the QPCR assay can be used to study cellular DNA damage in  
the specific genes after exposure to DNA damaging agents, such as cisplatin [33], carboplatin [33], 
nitrogen mustards [34,35], UV irradiation [36], chlorambucil [37], alkylbenzylguanine [38], and  
2-chloro-2-deoxyadenosine [39]. QPCR is a reliable method, equivalently sensitive to the ICP-MS 
method to analyze the incorporation of platinum-based drugs into the gene of interest [33]. The PCR 
was carried out under conditions that allowed for exponential amplification such that DNA damage 
will significantly reduce the amount of the amplified product. A QPCR study for ruthenium complexes 
has been previously reported and indicated that the ruthenium complexes reduced the amount of 
amplified DNA compared to the control untreated DNA [23]. As shown in Figure 8, the plots showed 
that DNA amplification decreased as the concentration of ethaRAPTA increased. DNA amplification 
was reduced by half at an approximate concentration of 300 μM for both ruthenium complexes. 
However, ethaRAPTA was only slightly more effective than RAPTA-C at blocking DNA replication. 
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Figure 8. Amplification products of DNA treated by ethaRAPTA and RAPTA-C were 
quantified, and the amount of DNA amplification (%) was plotted as a function  
of concentration. 
 
Induction of lesions with the 696-bp BRCA1 fragment can be quantitated by assuming a random 
(Poisson) distribution of damage [33]. The amounts of lesions per the BRCA1 fragment are calculated 
using the Poisson equation, Equation 2, as described in the Experimental Section. A relationship 
between the concentration of ethaRAPTA and ruthenated DNA is illustrated in Figure 9 and is used to 
estimate the amounts of DNA lesions in the BRCA1fragment. The results showed approximately one 
lesion per the BRCA1 fragment at 50% inhibition of DNA amplification. 
Figure 9. The number of lesions per the BRCA1 fragment induced by ethaRAPTA and 
RAPTA-C. Absorbance units were applied to a Poisson equation and plotted as a function 
of the concentration. 
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For cellular DNA damage, the MCF-7 or HT-29 cell lines were incubated with either ethaRAPTA 
or RAPTA-C before genomic DNA was extracted and analyzed. As shown in Figure 10A,B, two 
RAPTA complexes significantly reduced BRCA1 amplification of both the MCF-7 and HT-29 cells. 
The total amount of amplified PCR product was inversely proportional to the amount of DNA adducts 
within the specified BRCA1 fragment (Figure 11A,B). 
Figure 10. Cellular BRCA1 damage in MCF-7 (A) and HT-29 (B) cells. The cells were 
incubated with various concentrations of ethaRAPTA (200–400 μM) and RAPTA-C  
(200–1200 μM), respectively, at 37 C for 48 h in 5% CO2. Genomic DNA of the 
ruthenium-treated or untreated cells was isolated, and the 3426-bp fragment of the BRCA1 
exon 11 of the cells was then amplified by PCR, electrophoresed on 1% agarose gel, 
stained with ethidium bromide and then visualized under UV light. The amplification 
products were quantified using a Bio-Rad Molecular Imager, and the amount of DNA 
amplification (%) was plotted as a function of the concentration. 
 
(A) 
 
(B) 
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Figure 11. The number of lesions per the 3426-bp fragment of the BRCA1 exon 11 in 
MCF-7 (A) and HT-29 (B) cells calculated by the Poisson equation. 
 
(A) 
 
(B) 
EthaRAPTA blocked 50% DNA amplification of the BRCA1 exon 11 of MCF-7 cells at a 
concentration of 300 μM and that of HT-29 cells above 300 μM. Similarly, RAPTA-C exerted its 
inhibitory effect on DNA amplification at a concentration of 1000 μM and 500 μM for MCF-7 and 
HT-29 cells, respectively. However, an approximate 6- to 15-fold higher concentration of ethaRAPTA 
was required to achieve the 50% inhibition of DNA amplification in both cell lines. In addition, the 
ethacrynic acid alone did not interfere with DNA amplification (data not shown). 
The inhibition concentration of 50% cancer cell growth, as shown in Table 1, by ethaRAPTA was 
lower than that by RAPTA-C both in MCF-7 and HT-29 cell lines, indicating a higher efficiency of 
ethaRAPTA over RAPTA-C in inhibiting these cancer cell growths. The increased efficiency may be a 
function of the ligand substitution on an arene group of these RAPTA complexes and nature of  
the cells [19,40,41]. In ethaRAPTA, ethacrynate is hydrophobic [42], making the complex more 
hydrophobic than that of the RAPTA-C. Furthermore, ethacrynic acid has a unique ability to inhibit 
glutathione S-transferase [43], particularly with GST P1-1 [19,30,41,44,45] offering increased potency 
via protection against detoxification. Crystallographic studies showed ethaRAPTA coordinated with 
both Cys101 residues from the homodimer of GST P1-1 via a loss of the chloride ligands. The 
ethacrynate ligand inserted into the hydrophobic substrate binding site (H-site), which is part of the 
active site [46,47], produced an interaction that suggests the disruption of the c-Jun N-terminal kinase 
(JNK) inhibition elicited by GST P1-1 enzyme [48].  
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Table 1. Inhibition of cancer cell growth and DNA amplification by ethaRAPTA  
and RAPTA-C. 
Metal complexes 
50% Inhibition (μM) of 
DNA amplification 
50% Inhibition (μM) of 
cancer cell growth 
 MCF-7 HT-29 MCF-7 HT-29 
Cisplatin 25 [33] ND 36 17 
ethaRAPTA 300 >300 * 20 50 
RAPTA-C 1000 500 * >1600 500 
* ethaRAPTA above 300 μM and RAPTA-C above 600 μM (as shown in Figure 10B) precipitated 
in the growth medium of the cell culture. ND = not determined.  
It is observed that the degree of inhibition of DNA amplification by these two RAPTA complexes 
was lower in cancerous cells than in the isolated systems, possibly because of the interaction of the 
metal complexes with participating proteins [45] or the structure of the histone-bound DNA offering 
some protection [49]. It was also noted that in some incubations (ethaRAPTA above 300 μM and 
RAPTA-C above 600 μM, as shown in Figure 10B), the RAPTA complexes precipitated in the growth 
medium of the cell culture. In addition, ethaRAPTA has been shown to interact with proteins in the 
cell culture medium and such interactions are favored over DNA binding [30]. It is likely that 
ethaRAPTA interacts with numerous targets [17,30,45,50–56]. In addition, ethaRAPTA has been 
demonstrated to induce apoptosis in the cisplatin-resistant MCF-7 breast cancer cell line. This 
suggested that ethaRAPTA triggers multiple pathways toward apoptosis, including those involving 
endonuclease G, caspases, and c-Jun N-terminal kinase [46]. These data provided insights into the 
mode of action of ethaRAPTA to participating proteins as opposed to DNA [49]. Therefore, it could be 
possible that DNA is not the primary target for ethaRAPTA, based on our data of the inhibition of 
DNA amplification. 
3. Experimental Section 
3.1. Materials 
EthaRAPTA and RAPTA-C were prepared using literature protocols [15,41]. Taq DNA 
polymerase, PvuII, EcoO190I, dNTPs and Tris-HCl were from New England Biolabs. The nucleotide 
sequences of the forward and reverse primers were obtained from Invitrogen; RT-PCR: forward 
primer, 5'-AGCAGGGAGAAGCCAGAATTG-3' and reverse primer, 5'-TCAGTAGTGGCTGTGG 
GGGAT-3'; 696-bp BRCA1: forward primer, 5'-ATAAAATCGACAGGGATCCTTAGCAGGGAG 
AAGCCAGAATTG-3' and reverse primer, 5'-ACTTTGTGTTCATTTTCTAGATCAGTAGTGGCTG 
TGGGGGAT-3'; 3426-bp BRCA1 exon 11: forward primer, 5'-GCCAGTTGGTTGATTTCCACC-3' 
and reverse primer, 5'-GTAAAATGTGCTCCCCAAAAG-3'. All other reagents were of the highest 
purity grade. 
3.2. Preparation of the 696-bp BRCA1 Fragment (Exon 16–24, Nucleotide 4897–5592) 
RNA (mRNA) was extracted from white blood cells using an mRNA isolation kit and biotinylated 
oligo-dT (Qiagen). The purified mRNA was used for complementary DNA (cDNA) synthesis and the 
Int. J. Mol. Sci. 2012, 13 13195 
 
 
amplification of the 696-bp BRCA1 fragment (nucleotide 4897–5592) was performed with the Qiagen 
OneStep RT-PCR Kit (Qiagen). The RT-PCR mixture was prepared in a 1.5-mL microcentrifuge tube 
with a final volume of 50 mL, containing a 5 mL reaction buffer, 400 μM of each dNTP, 0.6 μM of 
forward primer, 0.6 μM of reverse primer, OneStep RT-PCR enzyme mix (Qiagen), and RNase-free 
H2O. The template RNA was finally added in order to initiate the PCR reaction using two-step thermal 
cycling. The first step comprised of one cycle at 48 C for 45 min, allowing for the synthesis of the 
first strand cDNA by the action of reverse transcriptase. The reverse transcriptase was inactivated at  
94 C for 2 min. The second step included 40 cycles of denaturation at 94 C for 30 s, annealing at  
60 C for 1 min, and extension at 68 C for 2 min. The extension of the final cycle was expanded to  
7 min. The amplified PCR product was subjected to gel electrophoresis in agarose at 80 V for 60 min. 
The gel was stained with ethidium bromide (EB), visualized under ultraviolet light (UV), and the DNA 
extracted with a gel extraction kit (Qiagen). The sequence of the purified 696-bp BRCA1 fragment  
was subsequently verified using an automated DNA sequencer (ABI PRISM™ 377 DNA Sequencer) 
with a PRISM™ Ready Reaction Dye Deoxy Terminator Cycle Sequencing Kit (Applied Biosystem,  
Foster City, CA, USA).   
To avoid the interaction between ruthenium atoms and salts in buffers, the purified 696-bp BRCA1 
fragment (3 μg) used in the following experiments was dissolved in double-distilled water and then 
incubated with various concentrations of ethaRAPTA at 37 C for 24 h in the dark. Ruthenated DNA 
was further characterized for adduct formation and in vitro inhibition of DNA amplification. 
3.3. Sequence Preference for EthaRAPTA Binding to the BRCA1 Fragment 
The ethaRAPTA-treated BRCA1 fragment control (non-ruthenated) was ethanol precipitated, 
resuspended in double-distilled water and the concentration of DNA was determined 
spectrophotometrically at 260 nm. Ruthenium-treated DNA (200 ng) was mixed with BigDye 
terminator in a PCR tube (20 μL) containing 5 pmol of forward primer (5'-GGAATTCCATA 
TGAGCAGGGAGAAG-3') or reverse primer (5'-ATTGGTTCTGCAGRCAGTAGTGGCT-3'),  
200 μM of each dNTP, 1.5 mM MgCl2, 1 mM Tris-HCl (pH 8.3), and 1 unit of Taq DNA polymerase. 
The reactions were subjected to temperature cycling using a Perkin-Elmer Model 9600 cycle (Applied 
Biosystem, Foster City, CA, USA). The reactions used followed the protocols in the literature [23]. 
3.4. Absorption Titration 
Absorption spectra were recorded on a Hewlett-Packard 8452A Diode Array Spectrophotometer 
using a cuvette of 10 mm path length. The absorption titration was performed with a solution of 1 mM 
ethaRAPTA in DMSO. The DNA solution of 4–17 μL (1 × 10−4–5 × 10−4 M) was added to the sample 
cell. The sample solution was mixed and allowed to equilibrate for 15 min before measurement.  
The data were then fitted to the following equation, Equation 1, to obtain the intrinsic binding  
constant, Kb [57]. 
[DNA]/(εa − εf) = [DNA]/(εb − εf) + 1/Kb(εb − εf) (1) 
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where εa, εf and εb are the apparent, free and bound metal complex extinction coefficients, respectively. 
From a plot of [DNA]/(εa − εf) vs. [DNA], a slope of 1/(εb − εf) is obtained. Kb is the ratio of slope and 
the intercept. 
3.5. Thermal Denaturation of RAPTA-BRCA1 Adducts 
The 696-bp BRCA1 fragment (3 μg) was incubated with 60 μM of ethaRAPTA or 30 μM RAPTA-C 
in 1000 μL of a reaction mixture at 37 C for 24 h in the dark. Thermal denaturation profiles were 
obtained by measuring the absorbance at 260 nm for solutions of the 696-bp BRCA1 fragment in the 
absence and presence of the RAPTA complexes with the temperature scanning of 20–100 C. The 
melting temperature (Tm) was taken as the mid-point of the melting curves. 
3.6. Quantification of DNA Lesions Using QPCR 
The quantitative PCR (QPCR) method was used to assess the polymerase inhibiting effect of DNA 
ruthenation. RAPTA-treated DNA was ethanol precipitated and centrifuged at 12,000g at 4 C for  
20 min. After drying, the DNA pellet was resuspended in 10 μL of double distilled water and the 
concentration of DNA was determined spectrophotometrically at 260 nm. The PCR mixture (50 μL) 
contained 100 ng of Ru-treated DNA, 0.5 μM of each forward and reverse primer, 200 μM of each 
dNTP, 2 mM MgCl2, and 1.5 units of Taq DNA polymerase. The PCR conditions were as follows:  
3 min at 94 C, 30 cycles of 45 s at 60 C, 45 s at 72 C, and a final extension for 10 min. The PCR 
products were separated by gel electrophoresis on 1% agarose at 80 V for 60 min. The gel was stained 
with ethidium bromide and visualized under UV light. 
Product amplification was measured directly from the agarose gel using a Bio-Rad Molecular 
Imager with Image Quant Software Bio-Rad GS-700 Imaging Densitometer with the Molecular 
Dynamics program (version 1.0.2, Bio-Rad, Hercules, CA, USA, 1994). The amount of amplification 
was represented by the units of absorbance of the amplified products. The quantitative PCR assay was 
further employed to estimate the number of lesions per strand. Based on the assumption that the lesions 
were randomly distributed [33], the Poisson equation, Equation 2, was used to calculate the lesion 
frequency per strand. 
S = −ln(Ad/A) (2) 
Where S is the lesion frequency/strand, A is the absorbance unit produced from a given amount of  
non-damaged DNA template, and Ad is the absorbance unit produced from a given amount of damaged 
DNA template (damaged by a particular dose of ethaRAPTA). Therefore, Ad/A is the fraction of  
non-damaged template at a given dose. 
3.7. Cell Culture 
A human breast adenocarcinoma cell line (MCF-7) and a human colon adenocarcinoma cell line 
(HT-29) were grown as monolayers in Dulbecco’s modified Eagle medium (DMEM) without phenol 
red, supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and incubated at  
37 C with 5% CO2. 
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3.8. Cell Treatment and Genomic DNA Preparation 
About 1 × 106 MCF-7 or HT-29 cells were seeded into each well of a 6-well flat-bottomed plate. 
The cells were treated with the RAPTA complexes at various final concentrations (0–400 μM for 
ethaRAPTA and 0–1000 μM for RAPTA-C), and incubated at 37 C for 48 h. Genomic DNA was 
prepared using a procedure modified from the literature methods [33,58]. The RAPTA-treated cells 
and untreated control cells were harvested and washed twice with 0.5 mL of phosphate-buffered saline 
(PBS). The cells were centrifugation at 3000g for 5 min and the pellet resuspended in a 1.5 mL 
microcentrifuge tube with 500 μL of a cell lysis buffer. The cell lysate was digested overnight at 37 C 
with 25 μL of 10% sodium dodecyl sulfate and 2 μL of a proteinase K solution. After digestion was 
completed, 140 μL of saturated NaCl (6 M) was added and shaken vigorously for 15 s, followed by 
centrifugation at 3000g for 20 min. The protein sediment was left at the bottom of the tube and the 
supernatant containing the DNA was transferred to another 1.5 mL microcentrifuge tube. DNA was 
precipitated by addition of 2 volumes of absolute ethanol and centrifuged at 13,000g at 4 C for  
20 min. The DNA pellet was washed twice with 70% ethanol, dried and resuspended in 100 μL of 
double distilled water. 
3.9. Quantification of DNA Lesions in Cancer Cells 
Exon 11 of the BRCA1 gene (3426 bp) is a model DNA target for studying the effect of the RAPTA 
complexes (ethaRAPTA and RAPTA-C) on DNA amplification. The total volume of the PCR mixture 
was 50 μL containing 400 ng of ruthenated genomic DNA template, 0.5 μM of each forward and 
reverse primer, 300 μM of each dNTP, 2 units of Phusion Hot Start DNA polymerase, 1.5 mM MgCl2, 
1xPhusion™ GC Buffer. The PCR conditions used for amplifying the RAPTA adduction were as 
follows: 3 min at 98 C; 30 cycles of 30 s at 60 C, 2 min at 72 C and a final extension for 7 min at  
72 C. PCR products were electrophoresed on 1% agarose gel at 100 V and stained with ethidium 
bromide. The resulting PCR products were visualized and quantitated using the QPCR analysis. 
3.10. Cytotoxicity Assays 
MCF-7 and HT-29 cells were cultured in Dulbecco’s modified Eagle medium (DMEM)  
(pH 7.2–7.4) without phenol red supplement with 10% FBS and 1% penicillin-streptomycin. All cells 
were incubated at 37 °C with 5% CO2. The logarithmically growing cells were detached using 0.25 g/L 
trypsin-ethylenediamminetetraacetic acid (EDTA) solution (Gibco, Birmingham, MI, USA), washed 
twice with supplemented medium and centrifuged at 1500g for 5 min at 25 °C. Cells were plated  
at density of 5 × 104 cells per well into flat-bottmomed 96-well microplates and cultured in  
incubator overnight at 37 °C. The ruthenium(II) complex (ethaRAPTA or RAPTA-C) with various 
concentrations was added in culture medium, and further incubated for 48 h. The medium  
was removed and washed twice with 100 μL of phosphate buffer saline (PBS). Then, the  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution (final concentration of 
0.5 mg/mL) was added to each well and incubated for 3–4 h. The MTT solution was gently removed 
and the formazan crystals were dissolved with 200 μL of dimethylsulfoxide solution (DMSO). 
Absorbance was measured at 570 nm using and automated microplate reader. The cell viability rate 
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was calculated as follows: cell viability (%) = (absorbance of the treated wells)/(absorbance of the 
control wells) × 100%. 
4. Conclusions 
The present study described a detailed investigation of the interaction of ethaRAPTA with the 
human BRCA1 gene fragment. We have characterized the ethaRAPTA interaction with DNA, 
including probing the sequence specific modified DNA structural stability and DNA amplification 
using the breast cancer suppressor gene 1 (BRCA1) of human breast and colon adenocarcinoma cell 
lines as models. The preference of ethaRAPTA base binding is in the order A > G > T > C. Once 
modified, the ethaRAPTA-induced BRCA1 structure has higher thermal stability than the related 
compound, RAPTA-C, modified equivalents. EthaRAPTA exhibits a higher efficiency than RAPTA-C 
in inhibiting BRCA1 amplification. With respect to both compounds, the inhibition of BRCA1 
amplification is more effective in an isolated system than in cell lines. These data provide evidence 
that will help to understand the process of elucidating the pathways involved in the response induced 
by ethaRAPTA. In addition, approaching such a gene as a potential molecular target for the novel 
antitumor ethaRAPTA could be of interest in cancer therapy. 
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